Jan 13, 2020 / 05:30PM GMT
Tycho W. Peterson - JP Morgan Chase & Co, Research Division - Senior Analyst
Okay. We're going to go ahead and kick it off. I'm Tycho Peterson from the life sciences team. It's my pleasure to introduce our next company this morning, Catalent. Breakout is going to be right after, across the hall in the Georgian room. And with that, let me turn it over to John.
John R. Chiminski - Catalent, Inc. - Chairman & CEO
Great. Good morning. Let me first draw your attention to a couple of pages here with regards to forward-looking statements and also non-GAAP financials. Thank you.
So Catalent is the leading global provider of advanced delivery technologies and drug development and manufacturing solutions. In fact, our pharmaceutical services is really powering the biotech, pharma and consumer health care customers across the drug development cycle, from preclinical all the way through to commercial manufacturing. We do this across all product types, now also including gene therapy. We have 1,100 active development projects within the company, which yield
Catalent Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers